Abstract 50P
Background
Papillary thyroid carcinoma (PTC) has a specific integrin expression signature that correlates with histopathology, specific driver gene mutations, and aggressiveness of the disease. α3β1 integrin is overexpressed, it is involved in PTC cell motility and invasion and is associated with an advanced disease and a worst outcome. Histopathology studies indicate that fibronectin 1 (FN1) and its integrin ligand αVβ3 are overexpressed in PTC. In normal thyroid cells, fibronectin (FN) stimulates DNA synthesis, proliferation and survival through αVβ3 binding.
Methods
The mRNA expression of integrins and FN1 genes in normal thyroid tissues and PTC were assessed in the TCGA database. -The level of FN and αVβ3 in was assessed by immunofluorescence in PTC cell lines (BCPAP, K1) and in a normal thyroid cell line (Nthy-ori3-1). -The release and deposition of FN were estimated by enzyme-linked immunoassay. - The proliferation was measured by MTT assay. -The silencing of gene FN1 in the K1 cell line was performed with KN2.0, non-homology mediated CRISPR knockout kit (ORIGENE®).
Results
Analysis of the TCGA database on 402 PTC and 82 healthy tissues demonstrates that FN1 mRNA is 60 times more expressed in PTC than in healthy tissue and that the ITGAV and ITGB1 subunits are more expressed. The increase in FN1 and ITGAV mRNA expression is associated with metastatic lymph nodes, more advanced staging, extrathyroidal extension, and higher risk. PTC cells show higher expression of integrin αVβ3, the main receptor of FN1 and at the same time a high production of fibronectin. The gene FN1 was silenced in K1 cell line (K1FN1-/-). Both K1 and K1FN1-/- seeded in collagen coated plates attached and survived in the absence of serum. While K1 proliferated under these culture conditions, proliferation was almost absent in K1FN1-/- and was rescued by soluble FN.
Conclusions
Papillary thyroid carcinoma cells express high amounts of αVβ3 integrin and produce more fibronectin. - Fibronectin/ αVβ3 interaction could be a mechanism of disease progression in PTC. - Fibronectin can be a powerful prognostic indicator and a site of pharmacological intervention.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
University of Salerno.
Funding
Department of Medicine, Surgery and Dentistry, University of Salerno.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4P - Predicting triple-negative breast cancer molecular subtype from hematoxylin and eosin using deep neural networks
Presenter: Nicola Occelli
Session: Cocktail & Poster Display session
Resources:
Abstract
5P - Onconaut: A precision medicine platform for oncology therapies
Presenter: Altuna Akalin
Session: Cocktail & Poster Display session
Resources:
Abstract
6P - Diagnostic accuracy of artificial intelligence in classifying HER2 status in breast cancer immunohistochemistry slides: A systematic review and meta-analysis
Presenter: Daniel Arruda Navarro Albuquerque
Session: Cocktail & Poster Display session
Resources:
Abstract
8P - Precision medicine drug testing platform to guide the treatment of EML4-ALK fusion lung cancers
Presenter: Sofia Merajver
Session: Cocktail & Poster Display session
Resources:
Abstract
9P - Circulating tumor cells and circulating tumor DNA detection in colorectal cancer stage III patients receiving three or six months of adjuvant treatment
Presenter: Asimina Koulouridi
Session: Cocktail & Poster Display session
Resources:
Abstract
10P - Novel theranostic agents in non-metastatic Egyptian breast cancer patients: miR-96, miR-1275, miR-4317 and miR-744
Presenter: Ahmed Mokhtar
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - A prospective study to evaluate the prognostic implications and molecular mechanism of SLC40A1 gene in primary acute myeloid leukemia
Presenter: Harsh Goel
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Prognostic value of PD-L1 expression and neutrophil-to-lymphocyte ratio to neoadjuvant chemo-immunotherapy in muscle-invasive urothelial carcinoma patients from the AURA trial
Presenter: Jeremy Blanc
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - Methylation of BRCA1 and RAD51C promoters determined by droplet digital PCR predicts homologous repair deficiency in patients with high-grade serous ovarian cancer: Results of the BOVARY-pilot study in paired FFPE and plasma samples and the ICL ovarian cohort
Presenter: Cassandra Michel
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - SLFN11 detection in patients with small cell lung cancer treated with lurbinectedin: A retrospective translational analysis
Presenter: Daniela Scattolin
Session: Cocktail & Poster Display session
Resources:
Abstract